What Coretta Scott King's Story Can Help Us Understand About Ovarian Cancer

What her family confirmed

Coretta Scott King died on January 30, 2006, at the age of 78. She was at a clinic in Rosarito, Mexico. In a statement the next day, the King family said she had gone there "for observation and consideration of treatment for ovarian cancer," and that doctors in the United States had considered her condition terminal.

She had a serious stroke in August 2005, and the cancer was diagnosed the same year. Doctors at the clinic told reporters she was partly paralyzed when she arrived and that no treatment was ever started. They gave the cause of death as respiratory failure, tied to both the stroke and the cancer.

That is the public record. This page adds nothing to it. What follows is about ovarian cancer, because that is where the useful information sits.

A cancer that hides behind ordinary symptoms

Ovarian cancer is grouped with two close relatives: fallopian tube cancer and primary peritoneal cancer. The three arise from similar tissue, behave alike and are treated the same way. Many high-grade cases now appear to start in the fallopian tube rather than the ovary itself.

The National Cancer Institute is blunt about the timing problem. These cancers may cause no early symptoms at all, and by the time symptoms appear the disease is often advanced. The symptoms NCI lists are ones almost everyone has had at some point:

• Pain, swelling or a feeling of pressure in the abdomen or pelvis.
• A sudden or frequent urge to urinate.
• Trouble eating, or feeling full quickly.
• A lump in the pelvic area.
• Gas, bloating or constipation.

Nothing on that list is specific to cancer. What matters is not the symptom but its behavior over time.

When to get checked

Make an appointment if any of these fit you:

• Bloating, pelvic pain or feeling full quickly that happens most days for more than two weeks and is new for you.
• Abdominal swelling that keeps building, or clothes that stop fitting at the waist.
• A new pelvic lump you can feel.
• Bloating plus a change in how often you urinate, lasting more than two weeks.

There is no screening test for ovarian cancer for women at average risk. That is a real gap, and it is why symptom patterns carry so much weight here. Our overview of ovarian cancer goes further into what raises risk.

How a diagnosis is reached

The first steps are a physical exam and a pelvic exam, in which a clinician feels the size, shape and position of the uterus and ovaries. Imaging usually follows. Ultrasound may be done over the abdomen or with a probe placed in the vagina, which gives a closer view.

A blood test called CA-125 measures a substance that cells release into the blood. A raised level can point to cancer, but it also rises with conditions such as endometriosis, so it is one input, not a verdict. CT, MRI, PET and a chest x-ray may be added to map how far the disease has gone.

The diagnosis itself needs tissue. In ovarian cancer that tissue is usually taken during the operation to remove the tumor, rather than in a separate biopsy first. Our page on the cancer diagnosis process explains why a pathology report, not a scan, is the moment things become definite.

Why surgery leads, and what "residual" means

Treatment for these cancers usually starts with surgery, and the goal has a name: cytoreductive surgery, also called debulking. The surgeon removes as much visible tumor as possible. Chemotherapy, usually a platinum drug paired with a taxane drug, follows or sometimes comes first.

The size of what is left behind matters enormously. NCI lists the amount of residual tumor after that first operation among the factors most tied to outcome, alongside age, general fitness, tumor grade and cell type, stage, and whether there is ascites, a build-up of fluid in the abdomen. Newer plans may add drugs called PARP inhibitors, especially when a BRCA gene change is present.

Who carries higher risk

Age is the biggest single factor: almost half of cases occur in women over 65. A first-degree relative with ovarian cancer, meaning a mother, sister or daughter, is the strongest family signal. About 20 percent of ovarian cancers run in families, and most of those are linked to changes in the BRCA1 or BRCA2 genes. Lynch syndrome, endometriosis, postmenopausal hormone therapy and high body mass index also appear on NCI's list.

Women with a known inherited risk are offered a different conversation than women at average risk, including genetic testing and risk-reducing options.

The survival picture

The American Cancer Society projects 21,010 new ovarian cancer cases in the United States in 2026 and 12,450 deaths, and SEER, the federal cancer statistics program, prints them. Only 22 percent are found while still confined to the ovary. Fifty-four percent have already spread to distant sites at diagnosis.

Five-year relative survival across all stages was 52.0 percent for women diagnosed from 2016 through 2022. About 1.1 percent of women are diagnosed at some point in life. Rates of new diagnoses and deaths are both falling.

Those figures describe a large group of women diagnosed years ago. They are not a forecast for any one person, and they say nothing about how a specific cancer will behave.

What this does not mean

King's illness was disclosed at the very end of her life, in a few sentences. It cannot show what an ovarian cancer diagnosis looks like for anyone else. Her stroke and her cancer were separate problems that happened to overlap, and the clinic's account of her final days is not a lesson about treatment choices.

A vague, persistent symptom is also not evidence of cancer. It is a reason to be examined, which is a different and much smaller thing. Feeling frightened while waiting for that appointment is ordinary, and our page on emotions and cancer covers that ground.

Sources

• https://www.nbcnews.com/id/wbna11110291
• https://www.npr.org/transcripts/5180768
• https://www.cancer.gov/types/ovarian/patient/ovarian-epithelial-treatment-pdq
• https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq
• https://seer.cancer.gov/statfacts/html/ovary.html

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.